collection
MENU ▼
Read by QxMD icon Read
search

Cutaneous lymphoma

shared collection
113 papers 25 to 100 followers
By Rosa Izu Dermatologist. Associated Professor of Dermatology. Medicine. Basque Country University
https://www.readbyqxmd.com/read/27821903/proteomic-approaches-to-biomarker-discovery-in-cutaneous-t-cell-lymphoma
#1
REVIEW
Alexandra Ion, Iris Maria Popa, Laura Maria Lucia Papagheorghe, Cristina Lisievici, Mihai Lupu, Vlad Voiculescu, Constantin Caruntu, Daniel Boda
Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. The rapidly expanding fields of proteomics and genomics have not only helped increase knowledge concerning the carcinogenesis and tumor biology of CTCL but also led to the discovery of novel markers for targeted therapy...
2016: Disease Markers
https://www.readbyqxmd.com/read/19208096/hypertriglyceridaemia-with-bexarotene-in-cutaneous-t-cell-lymphoma-the-role-of-omega-3-fatty-acids
#2
Antonino Musolino, Michele Panebianco, Enrico Zendri, Marcello Santini, Sergio Di Nuzzo, Andrea Ardizzoni
Bexarotene is approved for the treatment of cutaneous T cell lymphomas in patients refractory to at least one prior systemic therapy. Associated hypertriglyceridaemia requires monitoring, but can readily be managed with concomitant medication, such as fenofibrate. Here we report three cases of hypertriglyceridaemia secondary to bexarotene assumption, which was adequately managed with omega-3 fatty acids. If fenofibate-related side effects occur, or a statin is required to control low-density lipoprotein-cholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment...
April 2009: British Journal of Haematology
https://www.readbyqxmd.com/read/22678563/ten-year-experience-of-bexarotene-therapy-for-cutaneous-t-cell-lymphoma-in-finland
#3
Liisa Väkevä, Annamari Ranki, Sonja Hahtola
Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lym-phoma (CTCL). Literature on the efficacy, dosing and side-effects of bexarotene is sparse. We present here data on 37 Finnish patients with CTCL treated with bexarotene during the last 10 years. Bexarotene was equally effective as monotherapy or when combined with other treatment modalities, resulting in overall responses of approximately 75%. Early-stage CTCL responded better than advanced-stage CTCL (83% vs...
May 2012: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/16882161/minimizing-adverse-side-effects-of-oral-bexarotene-in-cutaneous-t-cell-lymphoma-an-expert-opinion
#4
REVIEW
C Assaf, M Bagot, R Dummer, M Duvic, R Gniadecki, R Knobler, A Ranki, P Schwandt, S Whittaker
Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies. However, bexarotene treatment is associated with unavoidable side-effects, in particular hypertriglyceridaemia and hypothyroidism, which are manageable with adequate concomitant medications and are reversible on cessation of treatment. A pragmatic strategy for minimizing bexarotene-associated hypertriglyceridaemia and hypothyroidism is suggested, based on data from the studies with bexarotene in CTCL and on day-to-day experience with this agent in the clinical setting...
August 2006: British Journal of Dermatology
https://www.readbyqxmd.com/read/20484880/evolution-of-clinical-and-molecular-responses-to-bexarotene-treatment-in-cutaneous-t-cell-lymphoma
#5
F Ballanger, J M Nguyen, A Khammari, B Dréno
BACKGROUND: The mechanisms of action of bexarotene are not well understood. METHODS: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Thirty-five patients were included. Twenty-three were treated with bexarotene for more than 3 months (300 mg/m(2)). In 7 patients, phototherapy was given with bexarotene. RESULTS: Dominant T-cell clones were observed in 11 patients in peripheral blood and in 19 patients in skin...
2010: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/24959987/rexinoids-isolated-from-sophora-tonkinensis-with-a-gene-expression-profile-distinct-from-the-synthetic-rexinoid-bexarotene
#6
Makoto Inoue, Hiroki Tanabe, Ken-ichi Nakashima, Yukihiro Ishida, Hitoshi Kotani
The retinoid X receptor (RXR) plays a critical role in transcriptional regulation via formation of an RXR homodimer or heterodimers with partner nuclear receptors. Despite the numerous beneficial effects, only a limited number of naturally occurring RXR agonists are known. In this report, two prenylated flavanones (1 and 2) isolated from Sophora tonkinensis were identified as new rexinoids that preferentially activated RXRs, relative to the retinoic acid receptor. The activities of 1 and 2 were the most potent among naturally occurring rexinoids, yet 2 orders of magnitude lower than the synthetic rexinoid bexarotene...
July 25, 2014: Journal of Natural Products
https://www.readbyqxmd.com/read/19845755/absence-of-modulation-of-cd4-cd25-regulatory-t-cells-in-ctcl-patients-treated-with-bexarotene
#7
Anne Chantal Knol, Gaëlle Quéreux, Anabelle Brocard, Fabienne Ballanger, Amir Khammari, Jean-Michel Nguyen, Brigitte Dréno
Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders, characterized by the infiltration of the epidermis by mature and activated malignant CD4+ T-lymphocytes. Retinoids such as retinoic acid and synthetic analogues have long been used alone or in combination with other therapies for CTCL. Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy. Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease despite improvement of cutaneous signs and symptoms were reported...
August 2010: Experimental Dermatology
https://www.readbyqxmd.com/read/24285015/final-results-of-phase-ii-trial-of-doxorubicin-hcl-liposome-injection-followed-by-bexarotene-in-advanced-cutaneous-t-cell-lymphoma
#8
MULTICENTER STUDY
D J Straus, M Duvic, S M Horwitz, K Hymes, A Goy, F J Hernandez-Ilizaliturri, T Feldman, B Wegner, P L Myskowski
BACKGROUND: High response rates for doxorubicin HCl liposome injection (DLI) in cutaneous T-cell lymphoma (CTCL) have been reported with vague criteria until recently. Approximately 50% of CTCL patients respond to bexarotene (Bex). PATIENTS AND METHODS: A phase II trial was carried out to clarify the true overall response rate (ORR) for DLI and to assess the role of sequential Bex. Patients were treated with DLI 20 mg/m(2) i.v. every 2 weeks for 16 weeks (8 doses) followed by 16 weeks with Bex 300 mg/m(2) orally...
January 2014: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27322928/fatal-case-of-primary-cutaneous-aggressive-t-cell-lymphoma-switching-from-a-cd4-to-a-cd8-phenotype-progressive-disease-with-bexarotene-and-romidepsin-treatment
#9
William T Johnson, Rebecca J Leeman-Neill, Parth Patel, Jonhan Ho, Lisa M Grandinetti, Jaroslaw Jedrych, Fiona E Craig
A 77-year-old white male presented to the clinic with two isolated cutaneous tumors on his forehead. A cutaneous biopsy showed a focally folliculotropic CD4 cutaneous lymphoma. The tumors were irradiated with a complete response, and he was started on oral bexarotene. He experienced localized cutaneous relapse 3 months into treatment. These new tumors now revealed a surprisingly CD8 cytotoxic phenotype, but with the same clone. A systemic workup was negative. His regimen was switched to romidepsin, and he was treated with local radiation again...
November 2016: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/27543197/phase-i-ii-study-of-the-oral-retinoid-x-receptor-agonist-bexarotene-in-japanese-patients-with-cutaneous-t-cell-lymphomas
#10
Toshihisa Hamada, Makoto Sugaya, Yoshiki Tokura, Mikio Ohtsuka, Ryoji Tsuboi, Tetsuo Nagatani, Mamori Tani, Mitsuru Setoyama, Shigeto Matsushita, Kazuhiro Kawai, Kentaro Yonekura, Tsuyoshi Yoshida, Toshiaki Saida, Keiji Iwatsuki
Safety, tolerability, pharmacokinetics and efficacy of bexarotene, a novel retinoid X receptor (RXR)-selective retinoid, were evaluated in Japanese patients with stage IIB-IVB and relapsed/refractory stage IB-IIA cutaneous T-cell lymphomas (CTCL). This study was conducted as a multicenter, open-label, historically controlled, single-arm phase I/II study. Bexarotene was p.o. administrated once daily at a dose of 300 mg/m(2) for 24 weeks in 13 patients, following an evaluation of safety and tolerability for 4 weeks at a dose of 150 mg/m(2) in three patients...
August 20, 2016: Journal of Dermatology
https://www.readbyqxmd.com/read/27648317/long-term-treatment-with-romidepsin-in-patients-with-peripheral-t-cell-lymphoma
#11
Claudius Irlé, Jonathan Weintraub
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options. Clinical studies have demonstrated the activity of romidepsin, a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor, in patients with relapsed or refractory AITL. In the case presented herein, we describe a patient treated with single-agent romidepsin at first diagnosis of AITL, resulting in complete remission for over 2 years and leading to the use of maintenance dosing...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/26547257/guidelines-for-phototherapy-of-mycosis-fungoides-and-s%C3%A3-zary-syndrome-a-consensus-statement-of-the-united-states-cutaneous-lymphoma-consortium
#12
REVIEW
Elise A Olsen, Emilia Hodak, Thomas Anderson, Joi B Carter, Marsha Henderson, Kevin Cooper, Henry W Lim
BACKGROUND: Ultraviolet light (UVL) is a long established treatment for mycosis fungoides (MF) and Sézary syndrome (SS), subtypes of cutaneous T-cell lymphoma (CTCL). Treatments have traditionally included broadband, narrowband ultraviolet B light (UVB) and psoralen plus ultraviolet A light photochemotherapy (PUVA), but more recently, treatment options have expanded to include UVA1 and excimer laser. UVL is used either as monotherapy or as an adjuvant to systemic therapy, demonstrating efficacy in many cases that equal or surpass systemic medications...
January 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27498959/cutaneous-peripheral-t-cell-lymphoma-not-otherwise-specified-a-single-center-prognostic-analysis
#13
Stanislav N Tolkachjov, Roger H Weenig, Nneka I Comfere
BACKGROUND: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a rare and aggressive disease either originating in or secondarily involving the skin. OBJECTIVE: We sought to assess clinical, histopathologic, and prognostic features of patients with cutaneous PTCL-NOS. METHODS: This was a retrospective chart review of patients with cutaneous PTCL-NOS between 1993 and 2013. RESULTS: Thirty patients with PTCL-NOS were included...
November 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27501224/cutaneous-t-cell-lymphoma-a-hypothesis-on-disease-pathophysiology-involving-deficiency-in-dna-repair
#14
K Thestrup-Pedersen
Cutaneous T-cell lymphoma (CTCL) is a rare disease occurring in Europe among two persons per million per year. It affects men more often than women (2:1). It is primarily a skin disease. In about 20% of patients, it becomes fatal with tumours in the skin and spreading to lymph glands. Approximately 3% of patients show a leukemic form called Sezary's syndrome, where malignant cells are present in blood with accompanying erythrodermia. CTCL is a T-lymphocyte disease occurring late in life as the average age of patients is around 66 years in Europe, Japan and the US...
October 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27151889/how-i-treat-mycosis-fungoides-and-s%C3%A3-zary-syndrome
#15
Sean Whittaker, Richard Hoppe, H Miles Prince
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related to a rare leukemic variant, Sézary syndrome (SS). MF patients at risk of disease progression can now be identified and an international consortium has been established to address the prognostic relevance of specific biologic factors and define a prognostic index. There are a lack of randomized clinical trial data in MF/SS and evidence is based on a traditional "stage-based" approach; treatment of early-stage disease (IA-IIA) involves skin directed therapies which include topical corticosteroids, phototherapy (psoralen with UVA or UVB), topical chemotherapy, topical bexarotene, and radiotherapy including total skin electron beam therapy...
June 23, 2016: Blood
https://www.readbyqxmd.com/read/27393975/a-new-protoparvovirus-in-human-fecal-samples-and-cutaneous-t-cell-lymphomas-mycosis-fungoides
#16
Tung G Phan, Brigitte Dreno, Antonio Charlys da Costa, Linlin Li, Patricia Orlandi, Xutao Deng, Beatrix Kapusinszky, Juliana Siqueira, Anne-Chantal Knol, Franck Halary, Jacques Dantal, Kathleen A Alexander, Patricia A Pesavento, Eric Delwart
We genetically characterized seven nearly complete genomes in the protoparvovirus genus from the feces of children with diarrhea. The viruses, provisionally named cutaviruses (CutaV), varied by 1-6% nucleotides and shared ~76% and ~82% amino acid identity with the NS1 and VP1 of human bufaviruses, their closest relatives. Using PCR, cutavirus DNA was found in 1.6% (4/245) and 1% (1/100) of diarrhea samples from Brazil and Botswana respectively. In silico analysis of pre-existing metagenomics datasets then revealed closely related parvovirus genomes in skin biopsies from patients with epidermotropic cutaneous T-cell lymphoma (CTCL or mycosis fungoides)...
September 2016: Virology
https://www.readbyqxmd.com/read/27653662/cutaneous-gamma-delta-t-cell-lymphoma-successfully-treated-with-brentuximab-vedotin
#17
Belen Rubio-Gonzalez, Jasmine Zain, Lino Garcia, Steven T Rosen, Christiane Querfeld
No abstract text is available yet for this article.
September 21, 2016: JAMA Dermatology
https://www.readbyqxmd.com/read/27247757/mogamulizumab-for-the-treatment-of-cutaneous-t-cell-lymphoma-recent-advances-and-clinical-potential
#18
REVIEW
Madeleine Duvic, Mark Evans, Casey Wang
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.
June 2016: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/26836950/phase-ii-multicentre-trial-of-oral-quisinostat-a-histone-deacetylase-inhibitor-in-patients-with-previously-treated-stage-ib-iva-mycosis-fungoides-s%C3%A3-zary-syndrome
#19
F Child, P L Ortiz-Romero, R Alvarez, M Bagot, R Stadler, M Weichenthal, R Alves, P Quaglino, M Beylot-Barry, R Cowan, L J Geskin, A Pérez-Ferriols, P Hellemans, Y Elsayed, C Phelps, A Forslund, M Kamida, P L Zinzani
BACKGROUND: Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. OBJECTIVES: To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). METHODS: Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles. Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT)...
July 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27732942/doxycycline-is-an-nf-%C3%AE%C2%BAb-inhibitor-that-induces-apoptotic-cell-death-in-malignant-t-cells
#20
Carolina V Alexander-Savino, Matthew S Hayden, Christopher Richardson, Jiyong Zhao, Brian Poligone
Cutaneous T-cell Lymphoma (CTCL) is a rare non-Hodgkin's lymphoma that can affect the skin, blood, and lymph nodes, and can metastasize at late stages. Novel therapies that target all affected disease compartments and provide longer lasting responses while being safe are needed. One potential therapeutic target is NF-κB, a regulator of immune responses and an important participant in carcinogenesis and cancer progression. As a transcription factor, NF-κB targets genes that promote cell proliferation and survival...
October 6, 2016: Oncotarget
label_collection
label_collection
2054
1
2
2016-10-26 15:56:11
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"